Fig. 2From: FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomideThe expression of FXYD2 mRNA in different histopathology and WHO grade in CGGA. The expression of FXYD2 mRNA in 516 glioma patients with different histopathology (A, B) and WHO grade (C) was compared by ANOVA. Data represent mean ± SDBack to article page